vs
Side-by-side financial comparison of CaliberCos Inc. (CWD) and MAXCYTE, INC. (MXCT). Click either name above to swap in a different company.
MAXCYTE, INC. is the larger business by last-quarter revenue ($4.8M vs $4.1M, roughly 1.2× CaliberCos Inc.). CaliberCos Inc. runs the higher net margin — -188.3% vs -200.5%, a 12.1% gap on every dollar of revenue. On growth, MAXCYTE, INC. posted the faster year-over-year revenue change (-20.9% vs -52.5%). Over the past eight quarters, MAXCYTE, INC.'s revenue compounded faster (-7.4% CAGR vs -57.6%).
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
CWD vs MXCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1M | $4.8M |
| Net Profit | $-7.7M | $-9.6M |
| Gross Margin | — | — |
| Operating Margin | -196.6% | -234.5% |
| Net Margin | -188.3% | -200.5% |
| Revenue YoY | -52.5% | -20.9% |
| Net Profit YoY | 32.2% | 9.4% |
| EPS (diluted) | $1.95 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.1M | $4.8M | ||
| Q3 25 | $3.6M | $4.6M | ||
| Q2 25 | $5.1M | $5.8M | ||
| Q1 25 | $7.3M | $5.7M | ||
| Q4 24 | $8.7M | $6.1M | ||
| Q3 24 | $11.3M | $5.6M | ||
| Q2 24 | $8.2M | $5.0M | ||
| Q1 24 | $23.0M | $5.6M |
| Q4 25 | $-7.7M | $-9.6M | ||
| Q3 25 | $-4.4M | $-12.4M | ||
| Q2 25 | $-5.3M | $-12.4M | ||
| Q1 25 | $-4.4M | $-10.3M | ||
| Q4 24 | $-11.4M | $-10.6M | ||
| Q3 24 | $146.0K | $-11.6M | ||
| Q2 24 | $-4.7M | $-9.4M | ||
| Q1 24 | $-3.8M | $-9.5M |
| Q4 25 | -196.6% | -234.5% | ||
| Q3 25 | -129.6% | -307.4% | ||
| Q2 25 | -112.4% | -244.3% | ||
| Q1 25 | -62.7% | -214.1% | ||
| Q4 24 | -236.8% | -213.1% | ||
| Q3 24 | 0.0% | -250.4% | ||
| Q2 24 | -65.0% | -241.0% | ||
| Q1 24 | -22.9% | -219.8% |
| Q4 25 | -188.3% | -200.5% | ||
| Q3 25 | -120.2% | -269.7% | ||
| Q2 25 | -104.5% | -212.2% | ||
| Q1 25 | -60.7% | -178.7% | ||
| Q4 24 | -247.6% | -175.0% | ||
| Q3 24 | 1.3% | -205.9% | ||
| Q2 24 | -57.8% | -188.8% | ||
| Q1 24 | -16.6% | -170.6% |
| Q4 25 | $1.95 | — | ||
| Q3 25 | $-1.65 | $-0.12 | ||
| Q2 25 | $-4.15 | $-0.12 | ||
| Q1 25 | $-3.85 | — | ||
| Q4 24 | $-10.15 | — | ||
| Q3 24 | $0.12 | $-0.11 | ||
| Q2 24 | $-4.34 | $-0.09 | ||
| Q1 24 | $-3.53 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.9M | $103.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3M | $171.5M |
| Total Assets | $135.4M | $202.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9M | $103.0M | ||
| Q3 25 | $10.9M | $105.7M | ||
| Q2 25 | $683.0K | $126.6M | ||
| Q1 25 | $1.6M | $138.3M | ||
| Q4 24 | $2.3M | $154.5M | ||
| Q3 24 | $1.6M | $153.8M | ||
| Q2 24 | $1.8M | $157.3M | ||
| Q1 24 | $2.1M | $157.5M |
| Q4 25 | $1.3M | $171.5M | ||
| Q3 25 | $4.2M | $180.3M | ||
| Q2 25 | $-19.9M | $190.7M | ||
| Q1 25 | $-15.8M | $199.4M | ||
| Q4 24 | $-12.6M | $206.3M | ||
| Q3 24 | $-3.8M | $213.3M | ||
| Q2 24 | $-4.7M | $221.3M | ||
| Q1 24 | $-745.0K | $226.4M |
| Q4 25 | $135.4M | $202.5M | ||
| Q3 25 | $82.6M | $213.5M | ||
| Q2 25 | $59.3M | $219.8M | ||
| Q1 25 | $103.6M | $230.0M | ||
| Q4 24 | $105.5M | $239.5M | ||
| Q3 24 | $158.6M | $248.6M | ||
| Q2 24 | $195.2M | $251.5M | ||
| Q1 24 | $201.5M | $257.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.1M | $-2.7M |
| Free Cash FlowOCF − Capex | — | $-2.9M |
| FCF MarginFCF / Revenue | — | -61.0% |
| Capex IntensityCapex / Revenue | — | 4.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-36.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.1M | $-2.7M | ||
| Q3 25 | $-4.6M | $-7.5M | ||
| Q2 25 | $-1.2M | $-9.9M | ||
| Q1 25 | $-1.7M | $-14.4M | ||
| Q4 24 | $555.0K | $-7.8M | ||
| Q3 24 | $-74.0K | $-4.4M | ||
| Q2 24 | $1.4M | $-4.8M | ||
| Q1 24 | $-1.5M | $-10.6M |
| Q4 25 | — | $-2.9M | ||
| Q3 25 | — | $-7.8M | ||
| Q2 25 | — | $-10.4M | ||
| Q1 25 | — | $-15.1M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | — | $-4.8M | ||
| Q2 24 | — | $-5.1M | ||
| Q1 24 | — | $-11.4M |
| Q4 25 | — | -61.0% | ||
| Q3 25 | — | -168.5% | ||
| Q2 25 | — | -179.2% | ||
| Q1 25 | — | -262.3% | ||
| Q4 24 | — | -131.6% | ||
| Q3 24 | — | -85.5% | ||
| Q2 24 | — | -103.3% | ||
| Q1 24 | — | -203.6% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 6.5% | ||
| Q2 25 | — | 10.0% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 14.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.51× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CWD
Segment breakdown not available.
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
